Content Reviewed By

Reviewed by a board-certified physician (Medical) · Reviewed by a licensed attorney specializing in mass tort litigation (Legal)

Home › Vision Loss from Diabetes Medication

Updated April 2026

Did Your Diabetes or Weight Loss Medication Cause Vision Loss?

Q: Can diabetes medication cause vision loss?

Yes. GLP-1 receptor agonist medications — including Ozempic, Wegovy, Mounjaro, and Trulicity — have been linked to NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy), a form of sudden, often permanent vision loss. A 2024 Harvard Medical School study published in JAMA Ophthalmology found semaglutide users had a 4-8x greater risk of NAION.

Q: Which diabetes medications are linked to vision loss?

GLP-1 receptor agonists including Ozempic (semaglutide), Wegovy (semaglutide), Mounjaro (tirzepatide), Zepbound (tirzepatide), Trulicity (dulaglutide), Rybelsus (semaglutide), Victoza (liraglutide), and Saxenda (liraglutide) have been linked to an elevated NAION risk in published research.

GLP-1 drugs including Ozempic, Wegovy, and Mounjaro have been linked to NAION — a form of sudden, often permanent vision loss. A Harvard study found users had a 4-8x greater risk of losing their vision.

Find Out If I Have a Claim → Check If You Qualify →

Free. No obligation. Takes 2 minutes.

✓ Harvard Study: 4x Vision Loss Risk · ✓ MDL 3163 — Cases Filing Now · ✓ Free & Confidential Review · ✓ No Cost Unless You Win

Can Diabetes Medications Cause Vision Loss?

If you're taking Ozempic, Wegovy, Mounjaro, or another GLP-1 medication — and you've experienced sudden vision loss — the connection may not be a coincidence. A landmark 2024 study from Harvard Medical School found that patients taking semaglutide had a dramatically elevated risk of NAION, a form of permanent vision loss.

NAION stands for Non-Arteritic Anterior Ischemic Optic Neuropathy — a condition where reduced blood flow to the optic nerve causes sudden, often irreversible vision loss. Many patients wake up one morning to find they've lost significant vision in one eye overnight. There is no FDA-approved treatment to restore the lost vision.

Despite the Harvard study's findings, Novo Nordisk has not updated US drug labels for Ozempic or Wegovy to warn about the NAION risk. Eli Lilly similarly has not warned about the risk for Mounjaro or Trulicity. Lawsuits are now pending in MDL 3163, the federal multidistrict litigation for GLP-1 NAION claims.

Key Facts: Vision Loss from GLP-1 Medications

Harvard study (JAMA Ophthalmology, July 2024): 4-8x elevated NAION risk in semaglutide users
NAION incidence: 8.9 per 10,000 in semaglutide users vs. 1.8 per 10,000 in non-users
NAION can cause permanent vision loss — no FDA-approved reversal treatment
MDL 3163 formed in 2026 — litigation is in early stages
Attorneys accepting cases on contingency — no upfront cost

Which GLP-1 Medications Are Linked to Vision Loss?

The following GLP-1 receptor agonist medications have been linked to NAION risk in published research or are included in MDL 3163:

Ozempic (semaglutide) — Novo Nordisk, weekly injection, type 2 diabetes
Wegovy (semaglutide) — Novo Nordisk, weekly injection, chronic weight management
Rybelsus (semaglutide oral) — Novo Nordisk, daily oral tablet
Mounjaro (tirzepatide) — Eli Lilly, weekly injection, type 2 diabetes
Zepbound (tirzepatide) — Eli Lilly, weekly injection, weight loss
Trulicity (dulaglutide) — Eli Lilly, weekly injection
Victoza (liraglutide) — Novo Nordisk, daily injection
Saxenda (liraglutide) — Novo Nordisk, weight loss

What Are the Symptoms of NAION?

NAION often develops suddenly, sometimes overnight. Common symptoms include:

Sudden, painless vision loss in one eye — often first noticed in the morning
Dark or blurry area in the visual field (especially the lower half)
Loss of peripheral vision in the affected eye
Complete or near-complete vision loss in severe cases
The other eye may be affected months or years later

If you experience any of these symptoms, seek immediate ophthalmologic evaluation. A prompt diagnosis is important for legal purposes as well as medical documentation.

Do You Qualify for a Vision Loss Lawsuit?

Qualifying Criteria

You were prescribed a GLP-1 medication (Ozempic, Wegovy, Mounjaro, Trulicity, Saxenda, Rybelsus, Victoza, or Zepbound)
You were diagnosed with NAION or sudden vision loss confirmed by an ophthalmologist
You are within your state's statute of limitations

Find Out If You Qualify — Free

Quick, confidential, no obligation.

By checking this box and clicking 'Submit My Claim,' I provide my express written consent to be contacted by Ruja Media LLC and its attorney network partners regarding my inquiry, including calls, text messages, and emails sent using automated technology. Consent is not a condition of purchase. Message and data rates may apply. I can revoke consent at any time. I consent to be contacted about my potential claim. Privacy Policy.

Frequently Asked Questions

Can diabetes medication cause vision loss?

Yes. GLP-1 receptor agonists including Ozempic, Wegovy, and Mounjaro have been linked to NAION — a form of sudden, often permanent vision loss. A 2024 Harvard study found a 4-8x greater risk in semaglutide users.

Which diabetes medications are linked to vision loss?

GLP-1 receptor agonists including Ozempic, Wegovy, Mounjaro, Trulicity, Zepbound, Rybelsus, Victoza, and Saxenda have been linked to elevated NAION risk in published research and are included in MDL 3163.

Is there a lawsuit for vision loss from diabetes medication?

Yes. MDL 3163 in the Eastern District of Pennsylvania consolidates GLP-1 NAION vision loss lawsuits. The litigation is in early stages. Attorneys are accepting cases on contingency — no upfront cost.

What are the symptoms of NAION?

NAION symptoms include sudden, painless loss of vision in one eye (often noticed upon waking), dark spots or shadows in the visual field, blurred vision, or loss of peripheral vision. Seek ophthalmologic evaluation immediately if you experience these symptoms.

→ Full GLP-1 Lawsuit Guide | NAION Lawsuit Guide | About NAION